Compare INUV & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | LGVN |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 21.4M |
| IPO Year | 1996 | 2021 |
| Metric | INUV | LGVN |
|---|---|---|
| Price | $0.59 | $2.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $11.00 | $3.00 |
| AVG Volume (30 Days) | 164.3K | ★ 280.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,209,305.00 | $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.57 | $0.48 |
| 52 Week High | $4.42 | $7.60 |
| Indicator | INUV | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 36.32 |
| Support Level | N/A | $0.61 |
| Resistance Level | $1.16 | $7.30 |
| Average True Range (ATR) | 0.04 | 0.47 |
| MACD | 0.01 | -0.52 |
| Stochastic Oscillator | 18.47 | 1.41 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.